Colin Goudelocke, MD, on 6-month data for batteryless neurostimulator

In this video, Colin Goudelocke, MD, gives an overview of the study “Treatment of OAB symptoms using Neuspera’s ultra-miniaturized system: 6-month results of the SANS-UUI phase II study,” which was presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2025 Winter Meeting. Goudelocke is a urologist with Ochsner Health Center in Covington, Louisiana.

Transcription:

Please provide an overview of this study and its notable findings.

This is the 6-month data of a new type of sacral neuromodulator that was created by a company called Neuspera. Most of the people in this space know that sacral neuromodulation has been around for a long time. Traditionally, a sacral neuromodulator is composed of 2 things, and that's the lead, the wire that actually stimulates the sample nerve, and then that's usually attached to a battery, or what is sometimes called the generator, which is typically, these days, buried in the fat around the upper part of the buttocks or the lower part of the waist. That's what we've all known as neuromodulation for a long time. And there have been some different iterations of that. Over time, that battery has shrunk down. I remember when I really first started doing this, a number of years ago, the battery was huge, and then it got a little bit smaller as battery technology got better, and then we even moved on to rechargeable batteries that were very small, and with the idea that we could decrease some of the negative aspects of that. This device is really unique. It gets rid of the battery altogether. The ultimate in making the battery really, really small is, well, what if we didn't have a battery at all? So it's very innovative in that way. It still has the lead. We still have to have a portion of it that sits next to the sacral nerve. But what they've done is they've actually integrated into that everything that you need, and so rather than having an internal power source that's supplied by a battery that might need to be either recharged every couple of weeks or changed every 10 or 15 or 20 years, the power source actually comes from an external source. It's externally driven, and so they have a small disc that you put on top of the device, so over the skin, and it's able to power that stimulation during that time. And, of course, there's a garment that that disc sits in, so you don't have to sit there holding it with your hand. You can walk around with it. You can clean the house or read a book or watch television or do whatever you want to do. That's the unique idea behind this, it's battery free, externally powered, and so it only requires a single incision. Normally, we make 2 incisions in order to place a neuromodulator: one incision for the for the lead, and then a second incision for the battery, no battery, so only a single lead, and you're also doing this in just a single step.This was a trial looking at efficacy, tolerability, all of those sorts of things. What we're talking about today is the 6-month data on that, and it's impressive. We'll get into the details of it, I'm sure, as we go through other questions. But essentially, this is what we've come to expect from sacral neuromodulation. At 6 months, 84% of patients respond, having at least a 50% reduction in their urgency incontinence episodes. I've been doing single neuromodulation for a long time. I've been either involved or reading about neuromodulation trials. This is kind of what you expect. This is the response that we would expect from that. It's very exciting. Those of us who do this a lot, we always feel like the more tools that we have in our toolbox, the better we're able to service our patients, because everybody who walks in the door doesn't need the same thing, and if I have different options for different people, I think I can do a lot more good for a lot more people.

This transcript was AI generated and edited by human editors for clarity.